Jay Clemens
The Defense Advanced Research Projects Agency and Massachusetts Institute of Technology have developed a biopharmaceutical production system meant to create treatments in the battlefield, Biopharma Reporter reported Tuesday.
Melissa Fassbender writes the system comprises a biologics expression system that produces therapeutic proteins and a microfluidic platform.
Tyler McQuade, program manager for DARPA’s battlefield medicine program, told Biopharma Reporter the development team incorporated end-to-end manufacturing processes such as synthesis, purification and formulation.
DARPA also invested in a project designed to develop biologics within eight hours using a portable kit in coordination with the University of Maryland, Fassbender reports.
